GENNEX share price, P/E, ROE & financials

Gennex Laboratories (BSE: GENNEX) had a P/E of 11.7× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 45% below their 52-week high. Sales and net profit grew 39% and 62% a year over 3 years; its ROCE of 10% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.34× equity. It is a small-cap company with a market cap of ₹219 Cr, ranked 93rd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 39% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹9.30
Day high: ₹9.40
Day low: ₹8.90
Prev. close: ₹9.25
Volume: 3 L

Health check

2 good · 4 to check

ReturnsBehind
−38.8% over a year, better than 0 of 7 peers.
Price tagCheaper
P/E 11.7 vs industry 28.7.
GrowthStrong
Sales +38.5%, profit +62.1% a year over 3 years.
ProfitabilityWeak
ROCE 10.1% vs peer median 17.9%.
Balance sheetStretched
Debt 0.34× equity, interest covered 6.7×, Piotroski 2 of 9.
Red flags1 to check
45% below its 52-week high.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹219 Cr, #93 of 154 in its industry by size.

Moves with the market

Beta 1.13 vs the NIFTY 50: tracks the market closely.

Key metrics

Last 12 months to Jun 2026: sales ₹178 Cr · profit ₹21 Cr

Market cap: ₹219 Cr; Small cap
P/E: 11.7; Industry 28.7
Price to book: 0.98; Peers 4.99
Dividend yield: 0.00%
ROE: 10.3%; Peers 14.7%
ROCE: 10.1%; Peers 17.9%
Debt to equity: 0.34; Debt ₹79 Cr
EPS (TTM): ₹0.77
OPM (TTM): 14.8%; Net margin 11.6%
Sales growth: +16.6%; Latest quarter vs a year ago
Profit growth: −7.0%; Latest quarter vs a year ago
Price to sales: 1.23; EV/EBITDA 11.7

Strengths

Quarterly sales up 16.6% on a year ago.
P/E of 11.7 against an industry P/E of 28.7.

Risks to check

45% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Gennex Laboratories

Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake…

Headquarters: Hyderabad
Employees: 125
Sector: Healthcare
ISIN: INE509C01026
Website: gennexlab.com

Price range

52 weeks

₹7.05₹16.30

Today

₹8.90₹9.40

Avg volume (3M): 6.7 L
1-year return: minus 38.8%
From 52-week high: minus 44.8%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
GENNEXGennex Laboratories	9.00	minus 2.70%	219	11.7	0.98	10.1%	10.3%	14.8%	38.5%	62.1%	0.00%	minus 38.8%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
34.2	37.2	40.4	61	39.8
29.1	29.7	31.8	55.1	35.5
5.1	7.6	8.6	5.9	4.4
14.8%	20.3%	21.2%	9.7%	11.0%
2.3	0	−0	1.3	2
1	1	1.1	1.1	0.9
0.5	0.5	0.5	1.2	0.6
–	–	−0.3	–	–
5.9	6.1	6.6	5	4.9
14.5%	9.1%	9.8%	4.2%	5.1%
5	5	5.2	4.5	4.7
0.21	0.21	0.22	0.16	0.19

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +38.5%
Profit CAGR 3Y: +62.1%
EPS CAGR 3Y: +39.5%
ROE: 10.3%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
65	79.1	138	173
–	+21.8%	+73.9%	+25.6%
60.3	62.1	121	151
4.7	17	16.7	21.9
7.2%	21.5%	12.2%	12.7%
3.7	4.3	10.5	8
1.4	3.1	3.6	4.2
0.9	2.4	2	2.6
0.3	0.6	−0	0.8
6.4	16.5	21.5	23.8
22.8%	20.1%	15.2%	9.5%
4.9	13.2	18.1	21
–	+167.7%	+37.6%	+15.8%
0.32	0.61	0.78	0.87

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
18	22.7	22.7	24.3
62.3	148	164	198
17.3	18.9	24.3	47.4
34.6	40.7	45.1	78.8
132	230	256	349
67.9	55.2	61.2	70.5
0	2.3	5.2	13.9
0	0	0	0
14.2	60.2	54.6	5.4
50.2	112	135	259
132	230	256	349

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
23.7	−46.7	−10.8	−63.7
−38.3	18.9	0.8	−4.8
21	73.7	4.6	65.3
6.4	45.9	−5.4	−3.2
−39.8	–	−8.9	−11.9
−16.1	−46.7	−19.7	−75.6

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders. Institutions hold about 0.0% (Yahoo estimate).

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you